Skip to main content

Table 2 Plan characteristics

From: Quantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and meningioma near optic tract

 

Meningioma

EQD22 (Gy)

Pituitary adenoma

EQD210 (Gy)

No of plan

11

  

10

  

Tumor

      

Volume of PTV

(cm3)

 

8.06 ± 2.45

  

9.53 ± 1.75

 

Prescribed dose

5

30 Gy/5 fr.

40

4

25 Gy/5 fr.

31.3

 

1

16 Gy/1 fr.

34.6

2

21 Gy/3 fr.

29.8

 

1

21 Gy/3 fr.

29.8

1

22.5 Gy/3 fr.

32.8

 

1

24 Gy/5 fr.

29.6

2

24 Gy/5 fr.

29.6

 

1

23 Gy/3 fr.

33.9

1

24 Gy/3 fr.

36

 

1

24 Gy/3 fr.

36

   

Minimal dose/prescribed dose

(%)

 

83.7 ± 9 range 72 - 90

  

80 ± 12 range 60 - 99

 

Maximal dose/prescribed dose

(%)

 

122 ± 15 range 110 - 157

  

129 ± 17 range 105 - 157

 

OARs

      

(Gy)

      

Left eye

 

0.12 - 2.25

  

0.02 - 4.48

 

Right eye

 

3.07 - 18.6

  

0.05 - 4.52

 

Brain stem

 

4.97 - 15.4

4.5 - 19.5

 

17.3 - 24.74

30.0 - 42.9

Optic chiasm

 

4.61 - 15.4

4.1 - 19.9

 

16.6 - 26.4

22 - 48

Left lens

 

0.01 - 2.00

  

0.03 - 4.08

 

Right lens

 

0.88 - 6.68

  

0.13 - 3.81

 

Left optic nerve

 

0.79 - 8.96

0.4 - 8.5

 

12.4 - 23.4

23 - 50

Right optic nerve

 

7.93 - 26.4

14.6 - 47.9

 

0.37 - 23.4

17.5 - 57.5

  1. EQD2 = n × d × (α/β+d)/(α/β+2), EQD210; α/β = 10 for PTV and EQD22; α/β = 2 for organs at risk
  2. OARs; organs at risk, fr.; fraction